Published on 9/03/2021 9:40:14 AM | Source: Motilal Oswal Financial Services Ltd

Healthcare Sector Update - IPM growth moderates further in Feb`21 By Motilal Oswal

Posted in Broking Firm Views - Sector Report| #Sector Report #Motilal Oswal Financial Services Ltd

Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel 

Download Telegram App before Joining the Channel

IPM growth moderates further in Feb’21

* IPM growth moderated further to 1.1% YoY in Feb’21 v/s 4.5% YoY in Jan’21 (12.1% in Feb’20).

* The Gastro, Derma, and VMN therapies exhibited growth of 9.9% YoY, 9.6% YoY, and 8.6% YoY, respectively. The Anti-Infective therapy declined 11.3% YoY vis-àvis decline of 2.7% YoY in Jan’21.

* Respiratory sales continued on the downtrend with 20.3% YoY decline in Feb’21.

* NLEM (~16% of IPM) declined 3% YoY, while non-NLEM (~84% of IPM) grew 2% YoY.

* On a MAT basis, industry growth came in at 1.9% YoY.


Price/NP growth offsets volume decline for 3M ended Feb’21

* For the 3M ended Feb’21, YoY growth stood at 4.7% YoY. YoY price growth of 4.9% and NP growth of 2.6% was offset, to some extent, by a YoY drop of 2.8% in volumes.

* For the 3M ended Feb’21, NLEM (~17% of IPM) grew 1.4% YoY and non-NLEM (~83% of IPM) was up 5.4% YoY.


Merck, Wockhardt, Ajanta, JB Chemicals, Biocon, and Ipca outperform

* In Feb’21, Merck India (+22.7% YoY), Wockhardt (+20% YoY), Ajanta Pharma (+15.7% YoY), JB Chemicals (+11.7% YoY), Biocon (+10% YoY), and Ipca (+9.7% YoY) delivered robust performances.

* Ajanta grew on a strong offtake in the Cardiac and Pain therapies (~50% of the therapy mix) of 20% and 22.7% YoY, respectively.

* Biocon’s growth was driven by Anti-Infectsives/Anti-Neoplasts (+75%/+22.6% YoY).

* Ipca posted good traction in the Pain/Analgesics (+20.5% YoY) and Gastro (22.2% YoY) segments.

* Lupin / Alembic / Dr Reddy’s reported below industry growth in Feb’21 (+0.5%/- 2.8%/-7.9% YoY) v/s +4.6%/+4.3/-3.6% in Jan’21.

* On a MAT basis, JB Chemicals / Merck / Torrent reported the highest price growth (+10.4%/7.5%/7% YoY). Glenmark saw the highest growth in new launches (+14.9% YoY).


Cardiac, Anti-Diabetic, and VMN drive overall sales growth on a MAT basis

* Chronic therapies saw strong growth – Cardiac / Anti-diabetic / VMN therapies exhibited growth of 12.5%/7.1%/6.7% YoY.

* Respiratory/Pain/Gynaec sales declined 5.4%/3.5%/3.2 YoY, impacting overall growth.




To Read Complete Report & Disclaimer Click Here


For More Motilal Oswal Securities Ltd Disclaimer SEBI Registration number is INH000000412


Above views are of the author and not of the website kindly read disclaimer

betvakti elexusbet gorabet maksibet maltcasino milosbet quennbet setrabet atlantisbahis artoscasino dumanbet elitbahis fashionbet favoribahis hiltonbet liderbahis oslobet romabet vegabet yorkbet kalebet bet10bet bahislion bahislion bahislion betpark dakikbet dumanbet fenomenbet holiganbet kalebet kolaybet lordbahis olabahis onwin piabet pusulabet süper10bet vipbahis supertotobet mariobet bahigo bahis siteleri güvenilir bahis siteleri kaçak bahis siteleri betist 1xbet asyabahis betebet betgaranti betlike betvole ligobet pinbahis polobet verabet